SCHEMBL3490336

SCHEMBL3490336

COc1cccc(CN2C(=O)N(Cc3ccccc3)c3cc(Cl)cc(N4CCNCC4)c3S2(=O)=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 1/20 0.44
GAA P10253 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
HTR6 P50406 3/20 0.42
USP2 O75604 4/20 0.42
ALDH1A1 P00352 4/20 0.42
CYP1A2 P05177 4/20 0.42
CYP3A4 P08684 4/20 0.42
CYP2D6 P10635 4/20 0.42
CYP2C19 P33261 4/20 0.42
HIF1A Q16665 3/20 0.42
TSHR P16473 2/20 0.42
CYP2C9 P11712 3/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490431 0.93 HTR3A (0.42) CMA1GAASIGMAR1HTR6ALDH1A1
SCHEMBL3490153 0.91 CMA1 (0.46) CMA1GAASIGMAR1HTR6USP2
SCHEMBL3489858 0.90 HTR6 (0.45) SLC6A2SLC6A4SIGMAR1HTR6
SCHEMBL3489612 0.88 HCRTR1 (0.46) CMA1GAASLC6A2SLC6A4HTR6
SCHEMBL3489321 0.87 HTR3E (0.43) SLC6A2SLC6A4SIGMAR1HTR6USP2
SCHEMBL3491519 0.86 EGFR (0.42) GAAHTR6MEN1KMT2A
SCHEMBL3490936 0.86 HTR6 (0.42) SLC6A2SLC6A4HTR6ALDH1A1LMNA
SCHEMBL3489196 0.85 CMA1 (0.51) CMA1GAASIGMAR1ALDH1A1LMNA
SCHEMBL3489119 0.85 HTR6 (0.43) SIGMAR1HTR6
SCHEMBL3490098 0.84 OPRD1 (0.41) HTR6ALDH1A1LMNATP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US claimed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D CMA1 917/4885GAA 4362/4885SLC6A2 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.